Ion Channels in Brain Metastasis.

Lukas Klumpp, Efe C Sezgin, Franziska Eckert, Stephan M Huber
Author Information
  1. Lukas Klumpp: Department of Radiation Oncology, University of Tübingen, 72076 Tübingen, Germany. lukas.klumpp@med.uni-tuebingen.de.
  2. Efe C Sezgin: Department of Radiation Oncology, University of Tübingen, 72076 Tübingen, Germany. efe.sezgin@uni-tuebingen.de.
  3. Franziska Eckert: Department of Radiation Oncology, University of Tübingen, 72076 Tübingen, Germany. franziska.eckert@med.uni-tuebingen.de.
  4. Stephan M Huber: Department of Radiation Oncology, University of Tübingen, 72076 Tübingen, Germany. stephan.huber@uni-tuebingen.de.

Abstract

Breast cancer, lung cancer and melanoma exhibit a high metastatic tropism to the brain. Development of brain metastases severely worsens the prognosis of cancer patients and constrains curative treatment options. Metastasizing to the brain by cancer cells can be dissected in consecutive processes including epithelial-mesenchymal transition, evasion from the primary tumor, intravasation and circulation in the blood, extravasation across the blood-brain barrier, formation of metastatic niches, and colonization in the brain. Ion channels have been demonstrated to be aberrantly expressed in tumor cells where they regulate neoplastic transformation, malignant progression or therapy resistance. Moreover, many ion channel modulators are FDA-approved drugs and in clinical use proposing ion channels as druggable targets for future anti-cancer therapy. The present review article aims to summarize the current knowledge on the function of ion channels in the different processes of brain metastasis. The data suggest that certain channel types involving voltage-gated sodium channels, ATP-release channels, ionotropic neurotransmitter receptors and gap junction-generating connexins interfere with distinct processes of brain metastazation.

Keywords

References

  1. EMBO J. 1999 Oct 15;18(20):5540-7 [PMID: 10523298]
  2. PLoS One. 2016 Mar 01;11(3):e0147489 [PMID: 26930581]
  3. Cell Physiol Biochem. 2010;26(4-5):597-608 [PMID: 21063097]
  4. PLoS One. 2012;7(5):e36923 [PMID: 22666335]
  5. Mol Cancer. 2014 Dec 11;13:264 [PMID: 25496128]
  6. Clin Cancer Res. 2005 Aug 1;11(15):5381-9 [PMID: 16061851]
  7. Breast Cancer Res Treat. 2012 Jul;134(2):603-15 [PMID: 22678159]
  8. Nat Commun. 2016 Feb 04;7:10339 [PMID: 26842342]
  9. J Biol Chem. 2015 May 8;290(19):11983-99 [PMID: 25805497]
  10. Mol Biol Cell. 2005 Jun;16(6):2972-83 [PMID: 15800067]
  11. Oncotarget. 2015 Oct 20;6(32):32914-29 [PMID: 26452220]
  12. J Cell Sci. 2013 Nov 1;126(Pt 21):4939-49 [PMID: 23986482]
  13. Drug News Perspect. 2003 Jun;16(5):291-8 [PMID: 12942160]
  14. Pflugers Arch. 2013 Aug;465(8):1209-21 [PMID: 23443853]
  15. Cancer Res. 2010 Sep 1;70(17):6957-67 [PMID: 20651255]
  16. BMC Neurol. 2015 Sep 24;15:171 [PMID: 26400041]
  17. Biochim Biophys Acta. 2013 Dec;1833(12):2961-9 [PMID: 23916755]
  18. Blood. 2008 Apr 15;111(8):3991-7 [PMID: 18192510]
  19. Am J Physiol Cell Physiol. 2016 Jul 1;311(1):C1-C14 [PMID: 27076614]
  20. Tumour Biol. 2015 Jun;36(6):4181-7 [PMID: 25775948]
  21. Int J Cancer. 2014 Nov 15;135(10):2338-51 [PMID: 24729314]
  22. Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2657-64 [PMID: 25445673]
  23. Int J Mol Sci. 2014 May 28;15(6):9519-30 [PMID: 24879524]
  24. Sci Rep. 2015 Nov 18;5:16758 [PMID: 26577038]
  25. PLoS One. 2015 Aug 25;10(8):e0136584 [PMID: 26305547]
  26. Pflugers Arch. 2015 Jul;467(7):1495-508 [PMID: 25163766]
  27. Int J Cancer. 2009 Jan 1;124(1):36-45 [PMID: 18844224]
  28. Anticancer Agents Med Chem. 2016;16(1):59-74 [PMID: 26299663]
  29. Brain Res. 2007 May 4;1144:33-41 [PMID: 17331483]
  30. Int J Alzheimers Dis. 2012;2012:868972 [PMID: 22675649]
  31. Radiother Oncol. 2011 Oct;101(1):122-6 [PMID: 21704404]
  32. Oncogene. 2011 Apr 28;30(17):2070-6 [PMID: 21170089]
  33. Nat Cell Biol. 2015 Jul;17(7):943-52 [PMID: 26098574]
  34. Psychiatry Res. 1984 Mar;11(3):259-69 [PMID: 6587418]
  35. Int J Cancer. 1992 Jan 2;50(1):103-7 [PMID: 1728600]
  36. Int J Oncol. 2016 Jan;48(1):73-83 [PMID: 26718772]
  37. Tohoku J Exp Med. 2014;234(1):29-40 [PMID: 25175030]
  38. Zh Vopr Neirokhir Im N N Burdenko. 2016;80(2):35-45; discussion 45-6 [PMID: 27070256]
  39. Biochem Biophys Res Commun. 2011 Aug 12;411(4):786-91 [PMID: 21798248]
  40. Mol Cancer. 2007 Mar 14;6:22 [PMID: 17359538]
  41. Oncogene. 2012 Apr 26;31(17):2237-46 [PMID: 21909135]
  42. Expert Rev Precis Med Drug Dev. 2016;1(3):235-243 [PMID: 27482545]
  43. Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):245-58 [PMID: 27365375]
  44. Cancer Lett. 2012 Oct 1;323(1):58-61 [PMID: 22484465]
  45. Pflugers Arch. 2015 Aug;467(8):1835-49 [PMID: 25277267]
  46. PLoS One. 2013 Dec 26;8(12):e83943 [PMID: 24386311]
  47. Nat Med. 2013 Sep;19(9):1161-5 [PMID: 23933981]
  48. Int J Mol Sci. 2013 Aug 20;14(8):17157-67 [PMID: 23965978]
  49. Nat Med. 2010 Jan;16(1):116-22 [PMID: 20023634]
  50. Cancer Control. 2004 May-Jun;11(3):165-73 [PMID: 15153840]
  51. Br J Pharmacol. 1997 Aug;121(8):1810-6 [PMID: 9283722]
  52. J Biol Chem. 2008 Dec 26;283(52):36234-40 [PMID: 18927085]
  53. Arch Biochem Biophys. 2015 Oct 1;583:18-26 [PMID: 26247838]
  54. Breast Cancer Res Treat. 2007 Jan;101(2):149-60 [PMID: 16838113]
  55. PLoS One. 2015 Dec 21;10(12):e0145259 [PMID: 26689552]
  56. Nature. 2016 May 18;533(7604):493-8 [PMID: 27225120]
  57. Mol Neurobiol. 2015 Aug;52(1):626-37 [PMID: 25249341]
  58. Pflugers Arch. 2016 May;468(5):751-62 [PMID: 26743871]
  59. Front Pharmacol. 2015 Nov 12;6:273 [PMID: 26834632]
  60. Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130105 [PMID: 24493753]
  61. J Biol Chem. 2009 Mar 27;284(13):8680-91 [PMID: 19176528]
  62. J Med Chem. 2013 Feb 14;56(3):593-624 [PMID: 23121096]
  63. J Nerv Ment Dis. 1964 Oct;139:381-6 [PMID: 14205646]
  64. J Biol Chem. 2009 Mar 20;284(12):8114-26 [PMID: 19136557]
  65. Oncotarget. 2016 Jun 14;7(24):36645-36654 [PMID: 27153560]
  66. Clin Exp Pharmacol Physiol. 2000 Nov;27(11):906-10 [PMID: 11071308]
  67. Biochem Biophys Res Commun. 2016 Sep 2;477(4):731-6 [PMID: 27353380]
  68. Oncogene. 2014 May 1;33(18):2307-16 [PMID: 23686305]
  69. Channels (Austin). 2012 Sep-Oct;6(5):352-61 [PMID: 22992466]
  70. Mol Cancer. 2015 Jan 27;14:13 [PMID: 25623198]
  71. Sci Rep. 2015 Aug 25;5:13450 [PMID: 26304588]
  72. Oxid Med Cell Longev. 2016;2016:8026702 [PMID: 26839633]
  73. Exp Biol Med (Maywood). 2008 Jul;233(7):779-91 [PMID: 18445774]
  74. Oncotarget. 2016 Mar 22;7(12):14259-78 [PMID: 26893360]
  75. Anticancer Res. 2011 Apr;31(4):1265-70 [PMID: 21508374]
  76. Cancer Res. 2001 Jan 1;61(1):333-8 [PMID: 11196183]
  77. Tumour Biol. 2014 Sep;35(9):8969-77 [PMID: 24903376]
  78. Biochim Biophys Acta. 2016 Jun;1863(6 Pt B):1385-97 [PMID: 26658642]
  79. Oncogene. 2004 Feb 19;23(7):1474-80 [PMID: 14973555]
  80. Radiother Oncol. 2012 Jun;103(3):373-9 [PMID: 22516777]
  81. Anticancer Res. 2006 Mar-Apr;26(2B):1567-75 [PMID: 16619573]
  82. J Biol Chem. 2006 Oct 6;281(40):29448-54 [PMID: 16873362]
  83. Cell Calcium. 2013 Apr;53(4):241-55 [PMID: 23357407]
  84. Neurosurg Rev. 2016 Jul 9;:null [PMID: 27392678]
  85. Cancer Cell. 2010 Jan 19;17(1):98-110 [PMID: 20129251]
  86. Oncoscience. 2014 Jan 10;1(1):82-94 [PMID: 25593989]
  87. Strahlenther Onkol. 2012 Jun;188(6):478-82 [PMID: 22418588]
  88. Ann Pharmacother. 2000 Jan;34(1):94-7 [PMID: 10669191]
  89. Cancer Biol Ther. 2012 Dec;13(14):1512-21 [PMID: 22990203]
  90. Lab Invest. 2013 Mar;93(3):344-53 [PMID: 23381625]
  91. Sci Rep. 2015 Sep 09;5:13861 [PMID: 26350345]
  92. Oncotarget. 2015 Jun 20;6(17):15566-77 [PMID: 25978028]
  93. Anticancer Drugs. 2007 Jan;18(1):23-8 [PMID: 17159499]
  94. Mol Cancer Res. 2015 Sep;13(9):1283-95 [PMID: 26041939]
  95. Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):984-9 [PMID: 24395782]
  96. Eur Biophys J. 2016 Oct;45(7):585-598 [PMID: 27165704]
  97. Int J Biochem Cell Biol. 2010 Feb;42(2):346-58 [PMID: 19948241]
  98. Front Physiol. 2013 Aug 14;4:212 [PMID: 23966948]

MeSH Term

Animals
Antineoplastic Agents
Brain Neoplasms
Humans
Ion Channels
Membrane Transport Modulators
Tumor Microenvironment

Chemicals

Antineoplastic Agents
Ion Channels
Membrane Transport Modulators

Word Cloud

Created with Highcharts 10.0.0brainchannelscancerprocessesionmetastaticcellstumorIontherapychannelvoltage-gatedsodiumBreastlungmelanomaexhibithightropismDevelopmentmetastasesseverelyworsensprognosispatientsconstrainscurativetreatmentoptionsMetastasizingcandissectedconsecutiveincludingepithelial-mesenchymaltransitionevasionprimaryintravasationcirculationbloodextravasationacrossblood-brainbarrierformationnichescolonizationdemonstratedaberrantlyexpressedregulateneoplastictransformationmalignantprogressionresistanceMoreovermanymodulatorsFDA-approveddrugsclinicaluseproposingdruggabletargetsfutureanti-cancerpresentreviewarticleaimssummarizecurrentknowledgefunctiondifferentmetastasisdatasuggestcertaintypesinvolvingATP-releaseionotropicneurotransmitterreceptorsgapjunction-generatingconnexinsinterferedistinctmetastazationChannelsBrainMetastasisBKCaKv101connexinpannexin

Similar Articles

Cited By